AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences

Wed Feb 27, 2013 7:30am EST

* Reuters is not responsible for the content in this press release.

For best results when printing this announcement, please click on the link
below:

http://pdf.reuters.com/pdfnews/pdfnews.asp?i=43059c3bf0e37541&u=urn:newsml:reuters.com:20130227:nPnSF67371


REDWOOD CITY, Calif.,  Feb. 27, 2013  /PRNewswire/ -- AcelRx Pharmaceuticals,
Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the
development and commercialization of innovative therapies for the treatment of
acute and breakthrough pain, today announced that AcelRx will present a
corporate overview at the following two investor conferences in  March 2013:

Cowen and Company 33rd  Annual Health Care Conference
Presenter:  Richard King, President and CEO
Date:  Wednesday, March 6, 2013  at  9:20 a.m. ET  (6:20 a.m. PT)
Location: Boston Marriott Copley Place -  Boston, Mass.

25th  Annual ROTH Conference  
Presenter:  James Welch, CFO
Date:  Wednesday, March 20  at  10:30 a.m. PT  (1:30 p.m. ET)
Location: The Ritz-Carlton,  Laguna Niguel,  Dana Point, CA

(Logo:  http://photos.prnewswire.com/prnh/20130226/MM67303LOGO)

All presentations will be webcast live and can be accessed through the investor
relations page at  www.acelrx.com.  For those not available to listen to the
live broadcast, a replay of the presentations will be archived and available
through  www.acelrx.com.

About AcelRx Pharmaceuticals, Inc.  
AcelRx Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on
the development and commercialization of innovative therapies for the treatment
of acute and breakthrough pain.  AcelRx's lead product candidate, the Sufentanil
NanoTab PCA System, which is currently in Phase 3 clinical development, is
designed to solve the problems associated with post-operative intravenous
patient-controlled analgesia which has been shown to cause harm to patients
following surgery because of the side effects of morphine, the invasive IV route
of delivery and the complexity of infusion pumps.  AcelRx has two additional
product candidates which have completed Phase 2 clinical development: ARX-02 for
the treatment of cancer breakthrough pain, and ARX-03 for mild sedation, anxiety
reduction and pain relief for patients undergoing painful procedures in a
physician's office.  AcelRx has completed enrollment in a Phase 2 study for a
fourth product candidate, ARX-04, a sufentanil formulation for the treatment of
moderate-to-severe acute pain, funded through a grant from USAMRMC.  For
additional information about AcelRx's clinical programs please visit 
www.acelrx.com.  

Forward Looking Statements  
This press release contains forward-looking statements, including, but not
limited to, statements related to planned or anticipated future clinical
development of AcelRx Pharmaceuticals' product candidates, and the therapeutic
potential of AcelRx Pharmaceuticals' product candidates.  These forward-looking
statements are based on AcelRx Pharmaceuticals' current expectations and
inherently involve significant risks and uncertainties.  AcelRx Pharmaceuticals'
actual results and the timing of events could differ materially from those
anticipated in such forward-looking statements as a result of these risks and
uncertainties, which include, without limitation, risks related to: the success,
cost and timing of AcelRx Pharmaceuticals' product development activities and
clinical trials; the market potential for its product candidates; and other
risks detailed in the "Risk Factors" and elsewhere in AcelRx Pharmaceuticals'
U.S. Securities and Exchange Commission filings, including its Current Report on
Form 8-K filed with the SEC on  December 7, 2012.  AcelRx Pharmaceuticals
undertakes no duty or obligation to update any forward-looking statements
contained in this release as a result of new information, future events or
changes in its expectations.  

SOURCE  AcelRx Pharmaceuticals, Inc.


Jim Welch, Chief Financial Officer, +1-650-216-3511, jwelch@acelrx.com

Comments (0)
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.